Vasoprotection may also account for reduction in hemorrhagic transformation after delayed recombinant tissue plasminogen activator (tPA or alteplase) administration (at 3 h post-stroke), at least in moderate sized thromboembolic strokes (52, 53). This evidence concerns the gene PLAT and Stroke.